1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
3.8. Product Pipeline Analysis
3.9. Incidence and Prevalence Analysis
3.10. Patent Analysis
4. TECHNOLOGICAL OUTLOOK
5. RNA-BASED THERAPEUTICS AND VACCINE TECHNOLOGIES MARKET BY PRODUCT TYPE
5.3. RNA Vaccines
5.4. Delivery Systems
6. RNA-BASED THERAPEUTICS AND VACCINE TECHNOLOGIES MARKET BY RNA TYPE
6.1. Introduction
6.2. mRNA
6.3. siRNA
6.4. miRNA
6.5. Antisense RNA
7. RNA-BASED THERAPEUTICS AND VACCINE TECHNOLOGIES MARKET BY APPLICATION
7.1. Introduction
7.2. Infectious Diseases
7.3. Oncology
7.4. Genetic Disorders
7.5. Rare Diseases
8. RNA-BASED THERAPEUTICS AND VACCINE TECHNOLOGIES MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. United Kingdom
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. India
8.6.3. Japan
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Moderna
10.2. BioNTech
10.3. CureVac
10.4. Alnylam Pharmaceuticals
10.5. Arrowhead Pharmaceuticals
10.6. Ionis Pharmaceuticals
10.7. Translate Bio
10.8. GSK
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES